<DOC>
<DOCNO>EP-0636133</DOCNO> 
<TEXT>
<INVENTION-TITLE>
SUBSTITUTED 3-PYRROLIDINYLTHIO-CARBAPENEMS AS ANTIMICROBIAL AGENTS.
</INVENTION-TITLE>
<CLASSIFICATIONS>A61K31397	A61K31397	A61K3140	A61K3140	A61P3100	A61P3100	A61P3104	C07D47700	C07D47700	C07D47720	C07D51900	C07D51900	C07D52100	C07D52100	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61K	A61K	A61K	A61K	A61P	A61P	A61P	C07D	C07D	C07D	C07D	C07D	C07D	C07D	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61K31	A61K31	A61K31	A61K31	A61P31	A61P31	A61P31	C07D477	C07D477	C07D477	C07D519	C07D519	C07D521	C07D521	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
A compound of formula (I), in which R
<
1
>
 is carboxy or protected carboxy, R
<
2
>
 is 1-hydroxyethyl, R
<
3
>
 is methyl, R
<
4
>
 is optionally substituted pyridyl(lower)alkyl, optionally N-substituted 2-oxopiperazin-1-yl-(lower)alkyl, optionally substituted imidazol-1-yl(C2-C3)alkyl, optionally substituted imidazol-5-yl(lower)alkyl, optionally substituted imidazol-2-yl-(lower)alkyl, optionally substituted pyrazol-4-(or 5-)yl(lower)alkyl, optionally substituted pyrazol-1-ylethyl, optionally substituted triazolyl(lower)alkyl, optionally substituted pyrimidinyl(lower)-alkyl, optionally substituted dihydropyrimidinyl(lower)alkyl, or optionally substituted (2,3-dihydroimidazo-[1,2-b]pyrazol-1-yl)ethyl, and R
<
5
>
 is hydrogen or imino-protective group, and pharmaceutically acceptable salts thereof, which have antimicrobial activity.
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
FUJISAWA PHARMACEUTICAL CO
</APPLICANT-NAME>
<APPLICANT-NAME>
FUJISAWA PHARMACEUTICAL CO., LTD.
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
HATTORI KOHJI
</INVENTOR-NAME>
<INVENTOR-NAME>
MATSUDA KEIJI
</INVENTOR-NAME>
<INVENTOR-NAME>
MURATA MASAYOSHI
</INVENTOR-NAME>
<INVENTOR-NAME>
NAKAJIMA TAKASHI
</INVENTOR-NAME>
<INVENTOR-NAME>
TSUTSUMI HIDEO
</INVENTOR-NAME>
<INVENTOR-NAME>
HATTORI, KOHJI
</INVENTOR-NAME>
<INVENTOR-NAME>
MATSUDA, KEIJI
</INVENTOR-NAME>
<INVENTOR-NAME>
MURATA, MASAYOSHI
</INVENTOR-NAME>
<INVENTOR-NAME>
NAKAJIMA, TAKASHI
</INVENTOR-NAME>
<INVENTOR-NAME>
TSUTSUMI, HIDEO
</INVENTOR-NAME>
</INVENTORS>
<DESCRIPTION>
 _ _DESCRIPTIONSUBSTITUTED 3-PY R0LIDINYLTHI0-CARB^PENEMS AS ANTIMICROBIAL AGENTS5TECHNICAL FIELDThe present invention relates to novel azabicyclo compounds and pharmaceutically acceptable salts 10 thereof.More particularly, it relates to novel 3-pyrrolidinylthio-l-azabicyclo[3.2.0]hept-2-ene-2- carboxylic acid compounds and pharmaceutically acceptable 15 salts thereof, which have antimicrobial activity to processes for the preparation thereof, to a pharmaceutical composition comprising the same, and to a use of the same as a medicament and in the treatment of infectious diseases in human being or animal.20INDUSTRIAL APPLICABILITYAccordingly, one object of the present invention is to provide novel 3-pyrrolidinylthio-l-azabicyclo- 25 [3.2.0]hept-2-ene-2-carboxylic acid compounds and pharmaceutically acceptable salts thereof, which are highly active against a number of pathogenic microorganisms and are useful as antimicrobial agents.30 Another object of the present invention is to provide processes for the preparation of novel ■ i 3-pyrrolidinylthio-l-azabicyclo[3.2.0]hept-2-ene-2- carboxylic acid compounds and salts thereof.35 

 A further object of the present invention is to provide a pharmaceutical composition comprising, as an active ingredient, said 3-pyrrolidinylthio-l-azabicyclo- [3.2.0]hept-2-ene-2-carboxylic acid compounds and pharmaceutically acceptable salts thereof.Still further object of the present invention is to provide a use of said 3-pyrrolidinylthio-l-azabicyclo- [3.2.0]hept-2-ene-2-carboxylic acid compounds and pharmaceutically acceptable salts thereof as a medicament and in the treatment of infectious diseases by pathogenic microorganisms in human being or animal.DISCLOSURE OF INVENTIONThe object 3-pyrrolidinylthio-1-azabicyclo[3.2.0]- hept-2-ene-2-carboxylic acid compounds are novel and can be represented by the following general formula:in which R is carboxy or protected carboxy,2R R2 is 1-hydroxyethyl, ,3 is methyl,R is optionally substituted pyridyl(lower)alkyl, optionally N-substituted 2- 

 oxopiperazin-1-yl(lower)alkyl, optionally substituted imidazol-,B--- l-yl(C2-C3)alkyl, n. optionally substituted imidazol- fX, 5 5-yl(lower)alkyl, optionally substituted imidazol-2-yl(lower)alkyl, optionally substituted pyrazol-4-(or 5-)yl(lower)alkyl,10 optionally substituted pyrazol-1- ylethyl, optionally substituted triazolyl(lower)alkyl, optionally substituted15 pyrimidiny1(lower)alkyl, optionally substituted dihydropyrimidinyl(lower)alkyl, or optionally substituted 2,3-dihydro-
</DESCRIPTION>
<CLAIMS>
CLAIMS
A compound of the formula
in which R is carboxy or protected carboxy, R
:
 is 1-hydroxyethyl, is methyl, is optionally substituted pyridyl(lower)alkyl, optionally N-substituted 2-oxopiperazin-l-yl- (lowe )alkyl, optionally subεtituted imidazol-1-yl(C
2
~C
3
)alkyl, optionally εubstituted imidazol- 5-yl(lower)alkyl, optionally subεtituted imidazol-2-yl(lower)alkyl, optionally εubεtituted pγrazol-4-(or 5-)yl(lower)alkyl, optionally εubstituted pyrazol-1-ylethyl, optionally subεtituted triazolyl(lower)alkyl, optionally substituted pyrimidinyl(lower)alkyl, optionally subεtituted dihydropyrimidinyl(lower)alkyl, or optionally substituted (2,3-dihydroimidazo[1,2-b]pyrazol- 1-yl)ethyl, and
R
"
 is hydrogen or imino-protective group. and pharmaceutically acceptable saltε thereof. 


The compound of Claim 1, wherein
R I
1
 is carboxy or esterified carboxy, A is pyridyl(lower)alkyl optionally substituted by the group consisting of lower alkyl, carbamoyKlower)alkyl, mono- or di(lower)alkylcarbamoyl(lower)alkyl and N-[hydroxy(lower)alkyl]carbamoyl(lower)alkyl; 2-oxopiperazin-l-yl(lower)alkyl optionally N-substituted by the group consisting of lower alkenyloxycarbonyl and lower alkyl; imidazol-l-yl(C
2
-C
3
)alkyl optionally substituted by the group consiεting of lower alkyl, carbamoyl, carbamoyl(lower)alkyl, hydroxy(lower)alkyl, lower alkoxy(lower)alkyl, cyano, amino(lower)alkyl, protected amino(lower)alkyl and carbamoyl(lower)alkenyl; imidazol-5-yl(lower)alkyl optionally εubεtituted by lower alkyl; imidazol-2-yl(lower)alkyl optionally substituted by the group consiεting of lower alkyl and carbamoyl(lower)alkyl; pyrazol-4-(or 5-)yl(lower)alkyl optionally substituted by lower alkyl; pyrazol-1-ylethyl optionally substituted by lower alkyl;
1,2,4-(or 1,2,3-)triazolyKlower)alkyl optionally substituted by lower alkyl; pyrimidinyl(lower)alkyl optionally subεtituted by lower alkyl; dihydropyrimidinyl(lower)alkyl optionally εubεtituted by lower alkyl; or (2,3-dihydroimidazo[1,2-b]pyrazol-l-yl)ethyl optionally εubstituted by lower alkyl; and
R iε hydrogen or esterified carboxy. 


3. The compound of Claim 2, wherein
R is carboxy or lower alkenyloxycarbonyl, and
5 R is hydrogen or lower alkoxycarbonyl.
4. The compound of Claim 3, wherein
R is carboxy,
4 R is pyridyl(C1-C2)alkyl optionally substituted by the group consiεting of methyl, carbamoylmethyl, N,N-dimethylcarbamoylmethyl and N-(2-hydroxyethyl)carbamoylmethyl and
R is hydrogen.
5. The compound of Claim 4, which is
(4R,5S,6S)-6-[ (IR)-1-hydroxyethyl]-4-methyl-3- [ (2R,4S)-2-{2-(l-methyl-3-pyridinio)ethyl}pyrrolidin
4-yl]thio-7-oxo-l-azabicyclo[3.2.0]
hept-2-ene-2- carboxylic acid chloride,
(4R,5S,6S)-2-[(2R,4S)-2-[2-{l-(N,N-dimethylcarbamoyl methyl)-3-pyridinio}ethyl]pyrrolidin-4-yl]
thio-6- [ (lR)-l-hydroxyethyl]-4-methyl-7-oxo-l-azabicyclo- [3.2.0]
hept-2-ene-2-carboxylic acid chloride,
(4R,5S ,6S)-6-[(IR)-1-hydroxyethyl]-4-methyl-3- [ (2R,4S)-2-{2-(l-carbamoylmethyl-3-pyridinio)ethyl}- pyrrolidin-4-yl]
thio-7-oxo-l-azabicyclo[3.2.0]hept-2 ene-2-carboxylic acid chloride,
(4R,5S,6S)-6-[ (IR)-1-hydroxyethyl]-4-methyl-3- [ (2R,4S)-2-{2-(l-carbamoylmethyl-4-pyridinio)ethyl}- pyrrolidin-4-yl]
thio-7-oxo-l-azabicyclo[3.2.0]hept-2 ene-2-carboxylic acid chloride,
(4R,5S,6S)-6-[(lR)-l-hydroxyethyl]-3-[(2R,4S)-2-[2- [1-{N-(2-hydroxyethyl)carbamoylmethyl}-3-pyridinio]
- 


ethyl]pyrrolidin-4-yl]
thio-4-methγl-7-oxo-l-aza- biσyclo[3.2.0]hept-2-ene-2-carboxγlic acid chloride,
(4R,5S,6S)-6-[(IR)-1-hydroxyethyl]-4-methyl-3- [(2R,4S)-2-{2-(1-methyl-2-pyridinio)ethyl}pyrr
olidin- 4-yl]thio-7-oxo-l-azabicyclo[3.2.0]
hept-2-ene-2- carboxylic acid chloride,
(4R,5S,6S)-6-[(lR)-l-hydroxyethγl]-3-[(2R,4S)-2-{2-. (l-carbamoylmethγl-2-pγridinio)ethyl}pyrrolidin-4- yl]
thio-4-methyl-7-oxo-l-azabicyclo[3.2.0]hept-2- ene-2-carboxγlic acid chloride,
(4R,5S,6S)-3-[(2R,4S)-2-(1-methyl-2-pyridinio)methyl- pyrrolidin-4-yl]thio-6-[(IR)-1-hydroxyethyl]
-4- methyl-7-oxo-l-azabicyclo[3.2.0]hept-2-ene-2- carboxylic acid chloride,
(4R,5S,6S)-3-[(2R,4S)-2-(1-methyl-3-pyridiniomethyl)- pγrrolidin-4-yl]thio-6-[(lR)-l-hydroxyethyl]
-4- methyl-7-oxo-l-azabicyclo[3.2.0]hept-2-ene-2- carboxylic acid chloride,
(4R,5S,6S)-6-[(lR)-l-hydroxγethyl]-3-[(2R,4S)-2-(l- methyl-4-pyridiniomethyl)pyrrolidin-4-yl]
thio-4- methγl-7-oxo-l-azabicyclo[3.2.0]hept-2-ene-2- carboxylic acid chloride,
(4R,5S,6S)-3-[(2R,4S)-2-(l-methyl-2- pyridinio)methγlpyrrolidin-4-yl]thio-6-[(IR)-1- hydroxyethyl]
-4-methyl-7-oxo-l-azabicyclo[3.2.0]hept- 2-ene-2-carboxγlic acid chloride, or
(4R,5S,6S)-3-[(2R,4S)-2-{2-(l- pyridinio)ethyl}pγrrolidin-4-yl]thio-6-[ (1R)-1- 



 hydroxyethyl]-4-methyl-7-oxo-l-azabicyclo[3.2.0]
hept 2-ene-2-carboxylic acid chloride.
The compound of Claim 3, wherein
R iε carboxy,
4 R lε 2-oxopιperazιn-l-ylmethyl
.optionally N-substituted by the group consistin of methyl and allyloxycarbonyl, and
R is hydrogen.
7. The compound of Claim 6, which is
(4R,5S,6S)-6-[ (IR)-1-hydroxyethyl]-4-methyl-3- [ (2S,4S)-2-(4-methyl-2-oxopiperazin-i-γl)methyl- pyrrolidin-4-yl]
thio-7-oxo-l-azabicyclo[3.2.0Jhept-2- ene-2-carboxylic acid hydrochloride,
(4r.,5S,65)-6-[(lR)-l-hydroxyethyl]-3-[(2S,4S)-2-(2-o- xopiperazin-l-yl)methylpyrrolidin-4-yl]
- thio-4-methyl-7-oxo-l-azabicyclo-
[3.2.0]hept-2-ene-2-carboxylic acid, or
(4R,5S,6S)-3-[ (2S,4S)-2-(4,4-dimethyl-2-oxo- piperazino)methylpyrrolidin-4-yl]thio-6-[ (1R)-1- hydroxyethyl]
-4-methyl-7-oxo-l-azabicyclo[3.2.0]hept-
2-ene-2-carboxylic acid.
The compound of Claim 3, wherein R is carboxy, is imidazol-l-yl(C
2
-C
3
)alkyl optionally substituted by the group consisting of methyl, carbamoyl, carbamoylmethyl, hydroxymethyl, methoxymethyl, cyano, aminopropyl, (allyloxycarbonylamino)propyl and carbamoylethenyl, and
R is hydrogen. 


9. The compound of Claim 8, which iε
(4R,5S,6S)-6-[(IR)-1-hydroxyethyl]-4-methyl-3- [(2R,4S)-2-{3-(3-methyl-l-imidazolio)propyl}- pyrrolidin-4-yl]
thio-7-oxo-l-azabicyclo[3.2.0]hept-2- ene-2-carboxylic acid chloride,
(4R,5S,6S)-3-[(2R,4S)-2-{3-(3-carbamoylmethyl-1- imidazolio)propyl}pyrrolidin-4-yl]thio-6-[(1R)-1- hydroxyethyl]
-4-methyl-7-oxo-l-azabicyclo[3.2.0]hept- 2-ene-2-carboxylic acid chloride,
(4R,5S,6S)-6-[(IR)-1-hydroxyethyl]-4-methyl-3- [(2R,4S)-2-{2-(3-methyl-1-imidazolio)ethyl}- pyrrolidin-4-yl]
thio-7-oxo-l-azabicyclo[3.2.0]hept- 2-ene-2-carboxylic acid chloride,
(4R,5S,6S)-3-[(2R,4S)-2-{2-(3-carbamoylmethγl-l- imiαazolio)ethyl}pyrrolidin-4-yl]thio-6-[(IR)-1- hydroxyethyl]
-4-methyl-7-oxo-l-azabicyclo[3.2.0]- hept-2-ene-2-carboxylic acid chloride,
(4R,5S,6S)-3-[(2R,4S)-2-{2-(3-methyl-2-hydroxymethyl- 1-imidazolio)ethyl}pyrrolidin-4-yl]thio-6-[(IR)-1- hydroxyethyl]
-4-methyl-7-oxo-l-azabicγclo[3.2.0]hept- 2-ene-2-carboxylic acid chloride,
(4R,5S,6S)-3-[(2R,4S)-2-{2-(2-carbamoyl-3- methyl-l-imidazolio)ethyl}pyrrolidin-4-yl]thio-6- [(IR)-1-hydroxyethyl]
-4-methyl-7-oxo-l-azabicyclo- [3.2.0]hept-2-ene-2-carboxylic acid chloride,
(4R,5S,6S)-6-[(lR)-l-hydroxyethyl]-3-[(2R,4S)-2-{3- (imidazol-l-yl)propyl}pyrrolidin-4-yl]
thio-4-methyl- 7-oxo-l-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid hydrochloride, 



(4R,5S,6S)-3-[(2R,4S)-2-{2-(5-hydroxymethyl-3- methyl-1-imidazolio)ethyl}pyrrolidin-4-yl]thio-6- [ (lR)-l-hydroxyethγl]
-4-methyl-7-oxo-l-azabicyclo- [3.2.0]hept-2-ene-2-carboxylic acid chloride,
(4R,5S,6S)-3-[ (2R,4S)-2-{2-(4-hydroxymethyl-3- methyl-l-imidazolio)ethyl}pyrrolidin-4-yl]thio-6- [ (IR)-l-hydroxyethyl]
-4-methyl-7-oxo-l-azabicyclo- [3.2.0]hept-2-ene-2-carboxylic acid chloride,
(4R,5S,6S)-3-[(2R,4S)-2-{2-(4-hydroxymethylimidazol- 1-yl)ethyl}pyrrolidin-4-yl]thio-6-[ (IR)-1- hydroxyethyl]
-4-methyl-7-oxo-l-azabicyclo- [3.2.0]hept-2-ene-2-carboxylic acid hydrochloride,
(4R,5S,6S)-3-[ (2R,4S)-2-{2-(5-methoxymethyl-3-methγl- l-imidazolio)ethyl}pyrrolidin-4-yl]thio-6-[ (IR)-1- hyd oxyethyl]
-4-methyl-7-oxo-l-azabicyclo[3.2.0]hept- 2-ene-2-carboxylic acid chloride,
(4R,5S,6S)-3-[ (2R,4S)-2-{2-(4-carbamoylmethyl-3- methyl-l-imidazolio)ethγl}pyrrolidin-4-yl]thio-6- [ (lR)-l-hydroxyethyl]
-4-methyl-7-oxo-l- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid chloride,
(4R,5S,6S)-3-[(2R,4S)-2-{2-(4-cyanoimidazol-l- yl)ethyl}pyrrolidin-4-yl]thio-6-[ (IR)-1- hγdroxyethyl]
-4-methyl-7-oxo-l-azabicyclo- [3.2.0]hept-2-ene-2-carboxylic acid hydrochloride,
(4R,5S,6S)-3-[(2R,4S)-2-{2-(4-cyano-3-methyl-l- imidazolio)ethyl}pyrrolidin-4-yl]thio-6-[ (1R)-1- hydroxyethyl]
-4-methyl-7-oxo-l-azabicyclo[3.2.0]hept- 2-ene-2-carboxylic acid chloride, 



(4R,5S,6S)-3-[(2R,4S)-2-{2-(2-carbamoylimidazol-l- γl)ethyl}pyrrolidin-4-yl]thio-6-[ (IR)-1- hydroxγethyl]
-4-methγl-7-oxo-l-azabicyclo-
[3.2.0]hept-2-ene-2-carboxylic acid hydrochloride,
(4R,5S,6S)-3-[(2R,4S)-2-{2-(2-hydroxymethylimidazol- 1-yl)ethγl}pyrrolidin-4-γl]thio-6-[(IR)-1- hydroxyethyl]
-4-methyl-7-oxo-l-azabicyclo- . [3.2.0]hept-2-ene-2-carboxylic acid hydrochloride,
(4R,5S,6S)-3-[(2R,4S)-2-{2-(imidazol-l- yl)ethyl}pyrrolidin-4-yl]thio-6-[ (IR)-1- hydroxyethy1]
-4-methyl-7-oxo-1-azabicyclo- [3.2.0]hept-2-ene-2-carboxylic acid hydrochloride,
(4R,5S,6S)-3-[(2R,4S)-2-[2-{3-(3-aminopropyl)-l- imidazolio}ethyl]pyrrolidin-4-yl]
thio-6-[ (IR)-1- hydro:-cyethyl]-4-methγl-7-oxo-l-azabicγclo- [3.2.0]
hept-2-ene-2-carboxylic acid chloride,
(4R,5S,6S)-3-[(2R,4S)-2-{2-(4-carbamoyl-3-methyl-l- imidazolio}ethyl]pyrrolidin-4-yl]
thio-6-[ (IR)-1- hydroxyethyl]-4-methyl-7-oxo-l-azabicyclo- [3.2.0]
hept-2-ene-2-carboxylic acid chloride,
(4R,5S,6S)-3-[(2R,4S)-2-{2-(4-(2-carbamoylethenyl)-3- -methyl-1-imidazolio)ethyl}pyrrolidin-4- yl]thio-6-[(IR)-1-hydroxyethyl]
-4-methyl-7-oxo-l- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid chloride, or
(4R,5S .6S)-3-[(2R,4S)-2-{2-(5-(2-carbamoylethenyl)- 3-methyl-l-imidazolio)ethγl}pyrrolidin-4-yl]thio-6- [ (IR)-1-hydroxyethyl]
-4-methyl-7-oxo-l-azabicyclo- [3.2.0]hept-2-ene-2-carboxylic acid chloride. 



10. The compound of Claim 3, wherein
R iε carboxy,
4 R lε ιmιdazol-5-ylmethyl optionally substituted by methyl, and R is hydrogen.
11. The compound of Claim 10, which is
(4R,5S,6S)-3-[ (2R,4S)-2-(l-methylimidazol-5- ylmethyl)pyrrolidin-4-yl]thio-6-[ (1R)-1- hydroxyethyl]
-4-methyl-7-oxo-l-azabicyclo[3.2.0]hept-
2-ene-2-carboxylic acid hydrochloride, or
(4R,5S,6S)-3-[(2R,4S)-2-(l,3-dimethyl-5- imidazoliomethyl)pyrrolidin-4-yl]thio-6-[ (1R)-1- hydroxyethyl]
-4-methyl-7-oxo-l-azabicyclo[3.2.0]hept- 2-ene-2-carboxylic acid chloride.
12. The compound of Claim 3, wherein
R1 is carboxy. R" is imidazol-2-yl(C
1
-C
3
)alkyl optionally substituted by the group consisting of methyl and carbamoylmethyl, and R is hydrogen.
13. The compound of Claim 12, which is
(4R,5S,6S)-3-[(2R,4S)-2-{2-(l,3-dimethyl-2- imidazolio)ethyl}pyrrolidin-4-yl]thio-6-[(IR)-1- hydroxyethyl]
-4-methyl-7-oxo-l-azabicyclo[3.2.0]hept- 2-ene-2-carboxylic acid chloride,
(4R,5S,6S)-3-[(2R,4S)-2-{2-(3-carbamoylmethyl-l- methyl-2-imidazolio)ethyl}pyrrolidin-4-yl]thio-6- [ (lR)-l-hydroxyethyl]
-4-methyl-7-oxo-l-azabicyclo- [3.2.0]hept-2-ene-2-carboxylic acid chloride, or 



 (4R,5S,6S)-6-[(lR)-l-hydroxyethyl]-3-[(2R,4S)-2- (1,3-dimethyl-2-imidazoliomethyl)pyrrolidin-4-yl]
- thιo-4-methyl-7-oxo-l-azabicyclo[3.2.0]hept-2-ene-2- carboxylic acid chloride. .
14. The compound of Claim 3, wherein
R is carboxy,
4 R is pyrazol-4-(or 5-)ylmethyl optionally substituted by methyl, and R is hydrogen.
15. The compound of Claim 14, which is (4R,5S,6S)-3-[(2R,4S)-2-(l,2-dimethγl-4- pyrazoliomethyl)pyrrolidin-4-yl]thio-6-[(IR)-1- hydroxyethyl]
-4-methyl-7-σxo-l-azabicyclo[3.2.0]- hept-2-ene-2-carboxγlic acid chloride, or
(4R,5S,6S)-3-[(2R,4S)-2-(l,2-dimethyl-5- pyrazoliomethyl)pyrrolidin-4-yl]thio-6-[(IR)-1- hydroxyethyl]
-4-methyl-7-oxo-l-azabicyclo[3.2.0]' hept-2-ene-2-carboxylic acid chloride.
16. The compound of Claim 3, wherein
R is carboxy, 4 R is 2-(pyrazol-l-yl)ethyl optionally substituted by methyl, and
R iε hydrogen.
17. The compound of Claim 16, which iε (4R,5S,6S)-6-[(I )-1-hydroxyethyl]-4-methyl-3-
[(2R,4S)-2-(2-(pyrazol-1-yl)ethyl}pyrrolidin- - yl]thio-7-oxo-l-azabicyclo[3.2.0]
hept-2-ene-2- carboxylic acid hydrochloride, or
(4R,5S,6S)-6-[(IR)-1-hydroxyethyl]-4-methyl-3- 



 [ (2R,4S)-2-{2-(2-methyl-l-pyrazolio)ethyl}pyrrolidin- 4-yl]thio-7-oxo-l-azabicyclo[3.2.0]
hept-2-ene-2- carboxylic acid chloride.
18. The compound of Claim 3, wherein
1 R ιε carboxy,
R,4
"*
 iε l,2,4-triazol-l-(or 5-)γl(C, -C
2
)alkγl or
1,2,3-triazol-l-ylmethyl, each of which is optionally substituted by methyl, and 5 R iε hydrogen.
19. The compound of Claim 18, which iε
(4R,5S,6S)-3-[(2R,4S)-2-{l,4-dimethyl-5-(l,2,4- triazolio)methyl}pyrrolidin-4-yl]thio-6-[ (1R)-1- hydroxyethyl]
-4-methyl-7-oxo-l-azabicyclo[3.2.0]hept-
2-ene-2-carboxylic acid chloride, or
(4R,5S,6S)-3-[(2R,4S)-2-{2-(l,2,4-triazol-l- yl)ethyl}pyrrolidin-4-γl]thio-6-[ (1R)-1- hydroxyethyl]
-4-methyl-7-oxo-l-azabicyclo[3.2.0]hept-
2-ene-2-carboxylic acid hydrochloride,
(4R,5S,6S)-3-[(2R,4S)-2-[2-{4-methyl-l-(l,2,4- triazolio)}ethyl]pyrrolidin-4-yl]
thio-6-[ (1R)-1- hydroxyethyl]-4-methyl-7-oxo-l-azabicyclo[3.2.0]
hept-
2-ene-2-carboxylic acid chloride,
(4R,5S,6S)-6-[ (IR)-1-hydroxyethyl]-4-methyl-3-
[(2R,4S)-2-{2-(1,2 ,3-triazol-l-yl)ethyl}pyrrolidin-4- yl]thio-7-oxo-l-azabicyclo[3.2.0]
hept-2-ene-2- carboxylic acid chloride, or
(4R,5S,6S)-6-[ (IR)-1-hydroxyethyl]-4-methyl-3- [ (2R,4S)-2-[2-{3-methyl-l-(1,2,3- triazolio)}ethyl]
pyrrolidin-4-yl]thio-7-oxo-l- 



 azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid chloride, which iε optionally contain (4R,5S,6S)-6- [(IR)-1-hydroxγethyl]
-4-methyl-3-[(2R,4S)-2-[2-{2- methyl-l-(1,2,3-triazolio)}ethyl]pγrrolidin-4- yl]
thio-7-oxo-l-azabicyclo[3.2.0]hept-2-ene-2- carboxylic acid chloride.
20. The compound of Claim 3 , wherein R iε carboxy, R iε pyrimidin-2(or 5)-ylmethyl optionally εubεtituted by methyl, and R iε hydrogen.
21. The compound of Claim 20, which is (4R,5S,6S)-3-[(2R,4S)-2-(pyrimidin-5- yl)methyl)pyrrolidin-4-yl]thio-6-[(IR)-1- hydroxyethyl]
-4-methyl-7-oxo-l-azabicyclo[3.2.0]hept- 2-er.e-2-carboxylic acid, or
(4R,5S,6S)-3-[(2R,4S)-2-(pyrimidin-2- yl)methyl)pyrrolidin-4-yl]thio-6-[(lR)-l- hydroxyethyl]
-4-methyl-7-oxo-l-azabicyclo[3.2.0]hept- 2-ene-2-carboxylic acid.
22. The compound of Claim 3, wherein
R iε carboxy,
4 R iε (1,6-dihydropyrimidin-5-yl)methyl optionally substituted by methyl, and 5 R is hydrogen.
23. The compound of Claim 22, which is
(4R,5S,6S)-3-[ (2R,4S)-2-{(1,6-dihydro-l- methylpyrimidin-5-yl)methyl}pyrrolidin-4-yl]thio-6- [(IR)-1-hydroxγethyl]
-4-methyl-7-oxo-l-azabicyclo- [3.2.0]hept-2-ene-2-carboxylic acid chloride. 



 24. The compound of Claim 3, wherein R is carboxy,
#
 R is 2-(2,3-dihydroimidazo[1,2—b]pyrazol-l-yl)ethyl 
j
 optionally subεtituted by methyl, and
5 R is hydrogen.
25. The compound of Claim 24, which is
{4R,5S,6S)-6-[ (IR)-1-hydroxyethyl]-4-methyl-3- [ (2R,4S)-2-{2-(5-methyl-2,3-dihydroimidazo[1,2-b]
-1- 10 pyrazolio)ethyl}pyrrolidin-4-yl]thio-7-oxo-l- azabicyclo[3.2.0]
hept-2-ene-2-carboxylic acid chloride.
26. A process for the preparation of a compound of the 15 formula :
1 "5 1 in which R , R , R , R , and R are each as defined in Claim 1, 25 or salts thereof, which comprises
(a) reacting a compound of the formula :

 wherein R , R
ώ
 and R are each as defined above, or a reactive derivative at the oxo group thereof or saltε thereof with a compound of the formula :
wherem R 4 and R5 are each aε defined above, or εaltε thereof to give a compound of the formula
wherem R 1 , R2 , R 3 , R 4 and R 5 are each as defined above , or salts thereof; and
(b) subjecting a compound of the formula

 wherein R 2, R3
"
 , R4 and R5 are each as defined above, and 


 is protected carboxy, 


 or salts thereof to removal reaction of the ccaarrbbooxxyy--pprrooltective group on R 3. to give a compound of the formula
COOH
wnere R 2, R3, R4 and R5 are each as defined above, or salts thereof; and
(c) subjecting a compound of the formula
wherein R , R , R and R are each as defined above, and 


 i.s imino-protective group, or salts thereof to removal reaction of the iimmiinnoo--pprrootteecctive group of R to give a compound of the formula

 wherem R 1 , R2 , R 3 and R 4 are each as defined above , or salts thereof ; and
(d) reducing a compound of the formula :
wherem R 1 , R2 , R 3 and R 5 are each as defined above,
, 4 R4 is optionally substituted pyridyl(lower)alkenyl, optionally N-substituted 2- oxopiperazin-l-yl(lower)alkenyl, optionally substituted imidazol-l-yl(C
2
~C
3
)alkenyl, optionally εubstituted imidazol-5-yl(lower)alkenyl, optionally substituted imidazol-2-yl(lower)alkenyl, optionally substituted pyrazol-4-(or 5-)yl(lower)alkenyl, optionally substituted pyrazol-1-ylethenyl, optionally substituted triazolyl(lower)alkenyl, optionally substituted pyrimidinyl(lower)alkenyl, optionally substituted dihydropyrimidinyl(lower)alkenyl, or optionally subεtituted 


 2,3-dihydroimidazo[1,2-b]pyrazol- 1-ylethenyl, or εalts thereof to give a compound of the formula
wherem R 1 , R2 , R 3 , R 4 and R 5 are each as defined above , or εalts thereof; and
(e) reacting a compound of the formula :
wherein R and R are each as defined above, and
R is pyridin-2-(or 3- or 4-)yl(lower)alkyl, N-(lower)alkyl-2-oxopiperazin-l-yl- (lower)alkyl, imidazol-1-yl(C
2
-C
3
)- alkyl, imidazol-2-(or 5-)yl(lower)- alkyl, pyrazol-1-ylethyl, pγrazol-4-(or 5-)yl(lower)alkyl, pyrimidinyl(lower)alkyl, 1,2,4-triazol-l-(or 5-)yl(lower)alkyl, 1,2,3-triazol-l-yl(lower)alkyl, or 2,3-dihydroimidazo[1,2-b]pyrazol-l-yl- 



 ethyl, each of which iε optionally εubεtituted by suitable εubεtituent(ε) , or salts thereof with a compound of the formula :
R
6
 - X
wherein R is lower alkyl, carbamoyKlower)alkyl, N,N-di(lower)alkylcarbamoyl(lower)- alkyl, N-[hydroxy(lower)alkyl]- carbamoyl(lower)alkyl or protected amino(lower)alkyl, and
X iε an acid reεidue, to give a compound of the formula
wherein R 1 c^l, R", R", R", R' and X are each aε defined above, and
R
b iε 2-(or 3- or 4-)pyridinio(lower)alkyl, N-(lower)alkyl-2-oxo-l-piperazinio- (lower)- alkyl, l-imidazolio(C
2
-C-,)- alkyl, 2-(or 5-)imidazolio(lower)- alkyl, (1-pyrazolio)ethyl, 4-(or 5-)pyrazolio(lower)alkyl, pyrimidinio(lower)alkyl, 1-(or 5-) (1,2,4-triazolio) (lower)alkyl, l-(1,2,3-triazolio) (lower)alkyl, or 2,3-dihydro-1-imidazo[1,2-b]pyrazolio- ethyl, each of which iε optionally substituted by suitable substituent(ε) , or saltε thereof; and 



 (f) subjecting a compound of the formula :
10 wherein R 1, R2, R3 and R5 are each as defined above, and 4 R is protected ammo(lower)alkyl- substituted pyridyl(lower)alkyl,
N-[protected amino(lower)alkyl]- 15 subεtituted 2-oxopiperazin-l-yl-
(lower)alkyl, protected amino(lower)alkyl- substituted imidazol-1-yl(C
2
~C_)alkyl, protected amino(lower) lkyl- 20 substituted imidazol-5-yl(lower)alkyl, protected amino(lower)alkyl- εubεtituted imidazol-2-yl(lower)alkyl, protected amino(lower)alkyl- substituted pyrazol-4-(or 5-)- 25 yl(lower)alkyl, protected amino(lower)alkyl- substituted pyrazol-1-ylethyl, protected amino(lower)alkyl- substituted triazolyl(lower)alkyl, 30 protected amino(lower)alkyl- substituted pyrimidinyl(lower)alkyl, protected amino(lower)alkyl- substituted dihydropyrimidinyl- (lower)alkyl , 35 or protected amino(lower)alkyl- 


 substituted 2,3-dihydroimidazo[1,2-b]- pyrazol-1-ylethyl, each of which is further optionally, subεtituted by suitable subεtituent(s) , or salts thereof to removal reaction of the amino-protec 4 ammo-protective group on R to give a compound of the formula
wherein R 1, R2, R3 and R5 are each as defined above, and 4 R, is amino(lower)alkyl-substituted pyridyl(lower)alkyl,
N-[amino(lower)alkyl]-sub- stituted-2-oxopiperazin-l-yl-
(lower)alkyl, amino(lower)alkyl-subs ituted imidazol-1-yl(C
2
-C
3
)alkyl, amino(lower)alkyl-substituted imidazol-5-γl(lower)alkyl, amino(lower)alkyl-substituted imidazol-2-yl(lower)alkyl, amino(lower)alkyl-subεtituted pyrazol-4-(or 5-)yl(lower)alkyl, amino(lower)alkyl-εubεtituted pyrazol-1-ylethyl, amino(lower)alkyl-substituted triazolyl(lower)alkyl, amino(lower)alkyl-substituted pyrimidinyl(lower)alkyl, amino(lower)alkyl-substituted 


 dihydropyrimidinyl(lower)alkyl, or amino(lower)alkyl-substituted 2,3- dihydroimidazo[l,2-b]pyrazol-l-ylethyl, each of which is further optionally
V substituted by suitable substituent(s) , or salts thereof; and
(g) reducing a compound of the formula

 *") "
*
) C *
*
" wherein R , R , R , R , R° and X are each as defined above, and A is lower alkylene, or salts thereof to give a compound of the formula :
R
l

 r -i -j c C wherein R , R
ώ
, R , R and R are each as defined above, or saltε thereof.
35 


27. A pharmaceutical composition comprising, as an active ingredient, a compound of claim 1, in admixture with a pharmaceutically acceptable carrier or excipient.
28. Use of a compound of claim 1 for the manufacture of a medicament for therapeutic treatment of infectious diseaεes.
29. A method for the treatment of infectious diseaεes which comprises administering a compound of claim 1 to human being or animal.
30. Uεe of a compound of claim.1 aε an antimicrobial agent. 

</CLAIMS>
</TEXT>
</DOC>
